KBC Group NV Purchases 1,127 Shares of Biohaven Ltd. (NYSE:BHVN)

KBC Group NV boosted its position in shares of Biohaven Ltd. (NYSE:BHVN) by 50.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,377 shares of the company’s stock after acquiring an additional 1,127 shares during the quarter. KBC Group NV’s holdings in Biohaven were worth $126,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Handelsbanken Fonder AB lifted its holdings in Biohaven by 20.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 20,700 shares of the company’s stock valued at $1,034,000 after purchasing an additional 3,500 shares during the last quarter. Diversified Trust Co bought a new stake in shares of Biohaven during the third quarter worth approximately $239,000. Cypress Wealth Services LLC acquired a new position in shares of Biohaven in the third quarter valued at approximately $224,000. Exchange Traded Concepts LLC increased its stake in shares of Biohaven by 15.9% during the third quarter. Exchange Traded Concepts LLC now owns 19,893 shares of the company’s stock worth $994,000 after purchasing an additional 2,728 shares during the period. Finally, Creative Planning lifted its holdings in Biohaven by 57.9% during the 3rd quarter. Creative Planning now owns 18,209 shares of the company’s stock worth $910,000 after purchasing an additional 6,674 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insider Activity at Biohaven

In related news, Director John W. Childs bought 29,000 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were bought at an average price of $35.94 per share, for a total transaction of $1,042,260.00. Following the transaction, the director now directly owns 2,368,741 shares of the company’s stock, valued at approximately $85,132,551.54. The trade was a 1.24 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.00% of the stock is owned by company insiders.

Biohaven Stock Performance

Shares of NYSE:BHVN opened at $38.40 on Friday. The firm has a market cap of $3.88 billion, a PE ratio of -4.11 and a beta of 1.28. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21. The firm’s fifty day moving average is $39.05 and its 200-day moving average is $42.56.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). Sell-side analysts forecast that Biohaven Ltd. will post -8.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on BHVN. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price target (up from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. HC Wainwright reiterated a “buy” rating and set a $59.00 price objective on shares of Biohaven in a research note on Tuesday, December 17th. TD Cowen upped their target price on Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. Thirteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $63.00.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.